Maraviroc exposure is influenced by exogenous thyrotoxicosis

David Metsu^{1

2}, Christian Aquilina³, Pierre Delobel^{4

5}, Peggy Gandia^{1

2}, Frédérique Savagner^{6

7}, Stéphanie Raymond^{5

8}, Philippe Caron^{7

9}, Guillaume Martin-Blondel^{4

5}

Affiliations

¹ Laboratory of Pharmacokinetics and Toxicology, Purpan Hospital, University Hospital of Toulouse.
² INTHERES UMR1436 INRA-ENVT.
³ Department of Dermatology, Paul Sabatier University and Larrey Hospital.
⁴ Department of Infectious Diseases, University Hospital of Toulouse.
⁵ Inserm U1043 - CNRS UMR 5282, Toulouse-Purpan Pathophysiology Center.
⁶ Biochemistry and Genetic Laboratory, Federative Institute of Biology, CHU Toulouse.
⁷ Team 6, Inserm UMR 1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), CHU Rangueil.
⁸ Department of Virology, CHU Purpan.
⁹ Department of Endocrinology and Metabolic Diseases, Pôle Cardiovascular and Metabolic, Larrey University Hospital, Toulouse, France.

David Metsu et al. AIDS. 2021.

. 2021 Mar 15;35(4):701-703.

doi: 10.1097/QAD.0000000000002754.

David Metsu^{1

2}, Christian Aquilina³, Pierre Delobel^{4

5}, Peggy Gandia^{1

2}, Frédérique Savagner^{6

7}, Stéphanie Raymond^{5

8}, Philippe Caron^{7

9}, Guillaume Martin-Blondel^{4

5}

¹ Laboratory of Pharmacokinetics and Toxicology, Purpan Hospital, University Hospital of Toulouse.
² INTHERES UMR1436 INRA-ENVT.
³ Department of Dermatology, Paul Sabatier University and Larrey Hospital.
⁴ Department of Infectious Diseases, University Hospital of Toulouse.
⁵ Inserm U1043 - CNRS UMR 5282, Toulouse-Purpan Pathophysiology Center.
⁶ Biochemistry and Genetic Laboratory, Federative Institute of Biology, CHU Toulouse.
⁷ Team 6, Inserm UMR 1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), CHU Rangueil.
⁸ Department of Virology, CHU Purpan.
⁹ Department of Endocrinology and Metabolic Diseases, Pôle Cardiovascular and Metabolic, Larrey University Hospital, Toulouse, France.

No abstract available

References

1. Lazzarin A, Reynes J, Molina JM, Valluri S, Mukwaya G, Heera J, et al. The maraviroc expanded access program – safety and efficacy data from an open-label study . HIV Clin Trials 2015; 16:10–21.
1. Llibre JM, Rivero A, Rojas JF, Garcia Del Toro M, Herrero C, Arroyo D, et al. Safety, efficacy and indications of prescription of maraviroc in clinical practice: factors associated with clinical outcomes . Antiviral Res 2015; 120:79–84.
1. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV 1 . Nat Med 2005; 11:1170–1172.
1. Perry CM. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection . Drugs 2010; 70:1189–1213.
1. Courlet P, Livio F, Guidi M, Cavassini M, Battegay M, Stoeckle M, et al. Polypharmacy, drug–drug interactions, and inappropriate drugs: new challenges in the aging population with HIV . Open Forum Infect Dis 2019; 6:ofz531.